Grifols is already the largest commercial plasma collector in Canada. Now it’s coming under renewed scrutiny after two Indigenous women died inside its collection centres in Winnipeg. Since 2022, the company has contracted with Canadian Blood Services. It runs a network of collection facilities around the country, including in Winnipeg. Rodiyat Alabede was a 22-year-old international student at the University of Winnipeg, studying to become a financial analyst. Tragically, he died just a few hours after he donated plasma on Oct 25.
The recent deaths have raised questions about the safety measures at Grifols. Donors are right to demand that the company provide greater transparency and accountability regarding donor safety. Conservative MP and physician Matt Strauss expressed concerns about allowing donors to be aware. He questioned whether donors are fully informed about how their donations may be used, particularly when many plasma-derived medicines are sold for a profit overseas. He stressed that informed consent should always be the basis for any donation.
Grifols pays donors $30-100 for each donation, based on volume and frequency of donation. Finally, many advocates are concerned that donors are misled about the ways their plasma products may be exported for corporate profit. This is especially troubling when it is countries such as China. This lack of transparency has raised further questions about the practices of Grifols, the contract developer keeping our IDARc under lock and key, and its operational procedures.
Mary Hughes, Grifols’ vice-president of sales for Canada, testified before the House of Commons health committee. After providing for context of the deaths and sharing how expectation was set and communicated to donors, she said that donors are literate enough to understand that there are risks associated with donating plasma, even the rare risk of death during the donation process. She stressed that the details on carriers’ commercial use of their donations are still murky.
“Madam Chair, when donors consent, they are informed that the plasma that they collect is intended for plasma-derived medicines for Canadian Blood Services,” – Mary Hughes
Recently, concern has grown over donor safety and whether health screenings prior to donating are sufficient. This has led to an investigation into Grifols’ practices. MP Strauss underscored the need to focus on keeping donors healthy. He sounded alarm bells over the prospect of a healthy person donor meeting with fatal outcomes during or soon after the donation procedure.
“I assume that your organization screens folks to make sure that they’re totally healthy, and she died either while hooked up to a donation machine or shortly after being disconnected,” – Matt Strauss
Grifols’ biologics manufacturing operations in Canada manufacture albumin, one of the most important and life-saving products made from plasma. Although this product is crucial to many lifesaving medical procedures, it’s simply stored up to be exported and profited off of in other countries. This emerging commercial aspect poses serious ethical dilemmas. Now donor awareness and the ramifications of financial transactions linked to their donations are coming to a head.
To counter burgeoning opposition, Hughes claimed that deaths related to plasma donations are very uncommon in Canada. She pointed out that Grifols ensures the safety of donors and follows strict health protocols at every step of the donation process.
“Today, there is no correlation between death and plasma collection,” – Mary Hughes
Meanwhile, Grifols and Canadian Blood Services are still working out their final deal. Then the health committee must re-deliver it by April 10. This agreement is central to clarifying the duties of each party. It describes the requirements for donor confidentiality and safety procedures.
The attention on Grifols comes amid a growing national conversation about the morality of paid plasma donations. Critics contend that these financial incentives prioritize financial motivations over donor safety and in turn force less transparent disclosures of potential harms. This development exposes a tremendous lack of transparency and coordination between plasma collection organizations and donors. This gap directly impacts the understanding of the health risk and the commercial reality behind the plasma-derived products.
Regulatory bodies, including the Department of Justice, are looking closely at Grifols’ demeanor. They’re pushing for more transparency and better protocols to protect donor health. These recent deaths underscore an urgent need for stringent compliance with safety standards. It’s imperative that we demand the same with every medical intervention.
